NO20050162L - Nye antagonister av CXCR3-bindene CXC-kjemokiner - Google Patents

Nye antagonister av CXCR3-bindene CXC-kjemokiner

Info

Publication number
NO20050162L
NO20050162L NO20050162A NO20050162A NO20050162L NO 20050162 L NO20050162 L NO 20050162L NO 20050162 A NO20050162 A NO 20050162A NO 20050162 A NO20050162 A NO 20050162A NO 20050162 L NO20050162 L NO 20050162L
Authority
NO
Norway
Prior art keywords
cxcr3
cxc chemokines
chemokines
binding
binding cxc
Prior art date
Application number
NO20050162A
Other languages
English (en)
Other versions
NO332309B1 (no
Inventor
Amanda Proudfoot
Marie Kosco-Vilbois
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20050162L publication Critical patent/NO20050162L/no
Publication of NO332309B1 publication Critical patent/NO332309B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)

Abstract

Nye antagonister av CXCR3-bindende CXCkjemokiner og spesielt humant CXCLI I kan oppnås gjennom dannelsen av mutanter av slike kjemokiner hvori bindingen til glykosaminoglykaner (GAG'er) er svekket som følge av ikke-konservative substitusjoner av aminosyrer involvert i denne interaksjonen. Forbindelser fremstilt i henhold til den foreliggende oppfinnelse kan anvendes for å blokkere aktiviteten til CXCR3-bindende CXCkjemokiner på CXCR3-uttrykkende celler og derved tilveiebringe terapeutiske preparater for anvendelse i behandlingen eller forebyggingen av sykdommer relatert til overdreven aktivert T-cellemigrering, slik som ved transplantatavstøtning og autoimmune sykdommer, og av sykdommer med behov for økt vaskularisering, slik som ischemisk hjertesykdom.
NO20050162A 2002-06-12 2005-01-12 Antagonister av CXCRX3-bindene CXC-kjemokiner, samt fremgangsmate for fremstilling derav, DNA molekyler kodende for nevnte antagonister, ekspresjonsvektor, vertcelle, farmasoytisk preparat og anvendelse av nevnte antagonister. NO332309B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100697 2002-06-12
PCT/EP2003/050211 WO2003106488A2 (en) 2002-06-12 2003-06-03 Novel antagonists of cxcr3-binding cxc chemokines

Publications (2)

Publication Number Publication Date
NO20050162L true NO20050162L (no) 2005-01-12
NO332309B1 NO332309B1 (no) 2012-08-20

Family

ID=29724537

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050162A NO332309B1 (no) 2002-06-12 2005-01-12 Antagonister av CXCRX3-bindene CXC-kjemokiner, samt fremgangsmate for fremstilling derav, DNA molekyler kodende for nevnte antagonister, ekspresjonsvektor, vertcelle, farmasoytisk preparat og anvendelse av nevnte antagonister.

Country Status (16)

Country Link
US (1) US7541435B2 (no)
EP (1) EP1515990B1 (no)
JP (1) JP4394569B2 (no)
AR (1) AR040200A1 (no)
AT (1) ATE359297T1 (no)
AU (1) AU2003255505B2 (no)
CA (1) CA2489298C (no)
CY (1) CY1106799T1 (no)
DE (1) DE60313168T2 (no)
DK (1) DK1515990T3 (no)
ES (1) ES2282666T3 (no)
IL (1) IL165727A (no)
NO (1) NO332309B1 (no)
PT (1) PT1515990E (no)
SI (1) SI1515990T1 (no)
WO (1) WO2003106488A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
EP1723970A4 (en) * 2004-03-09 2009-08-12 Univ Kyoto MEDICAL COMPOSITION WITH CXCR3 INHIBITOR
ITFI20040243A1 (it) * 2004-11-25 2005-02-25 Paola Romagnani Metodo diagnostico per la previsione di rigetto di organo trapiantato
WO2006069449A1 (en) * 2004-12-29 2006-07-06 The University Of British Columbia Chemokine receptor-independent immunomodulatory and anti-proliferative activity
JP2008545396A (ja) * 2005-05-18 2008-12-18 インターミューン インコーポレイテッド 非天然ケモカイン受容体リガンドおよびこれらの使用方法
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
US8263064B2 (en) 2007-06-04 2012-09-11 Rappaport Family Institute For Research In The Medical Sciences Method of suppressing disease severity of multiple sclerosis using chemokine CXC11
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US20220281934A1 (en) * 2019-08-29 2022-09-08 Antagonis Biotherapeutics Gmbh T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB202214951D0 (en) * 2022-10-11 2022-11-23 Univ London Queen Mary CXC receptor ligands

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US5656724A (en) * 1994-10-26 1997-08-12 Repligen Corporation Chemokine-like proteins and methods of use
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US5977334A (en) * 1997-09-11 1999-11-02 The Cleveland Clinic Foundation DNA encoding a chemokine, Beta R1, comprising the Beta R1 promoter
WO2001078708A1 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
MXPA03000310A (es) * 2000-07-12 2004-12-13 Gryphon Therapeutics Inc Quimiocinas sinteticas bioactivas, modificadas con polimeros y metodos para su elaboracion y uso.
MXPA03004913A (es) 2000-12-01 2003-09-05 Schering Corp Usos de genes de mamifero y reactivos relacionados.

Also Published As

Publication number Publication date
EP1515990A2 (en) 2005-03-23
DE60313168T2 (de) 2007-12-20
ATE359297T1 (de) 2007-05-15
AR040200A1 (es) 2005-03-16
AU2003255505B2 (en) 2009-01-08
JP4394569B2 (ja) 2010-01-06
DK1515990T3 (da) 2007-06-11
PT1515990E (pt) 2007-05-31
IL165727A (en) 2010-05-17
AU2003255505A1 (en) 2003-12-31
IL165727A0 (en) 2006-01-15
US7541435B2 (en) 2009-06-02
DE60313168D1 (de) 2007-05-24
NO332309B1 (no) 2012-08-20
CY1106799T1 (el) 2012-10-24
EP1515990B1 (en) 2007-04-11
SI1515990T1 (sl) 2007-08-31
US20060204498A1 (en) 2006-09-14
JP2006511200A (ja) 2006-04-06
WO2003106488A3 (en) 2004-04-15
WO2003106488A2 (en) 2003-12-24
CA2489298C (en) 2012-09-11
CA2489298A1 (en) 2003-12-24
ES2282666T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
NO20050162L (no) Nye antagonister av CXCR3-bindene CXC-kjemokiner
ATE506375T1 (de) Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung
JOP20220152A1 (ar) مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها
BR0016154A (pt) Depsipeptida e seus congêneres papa uso como imunossupressores
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
BR0207952A (pt) Moduladores da atividade de receptores de quimiocina
DE602004023725D1 (de) Muteine von tränen-lipocalin
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
HUP0003505A2 (hu) Aminoterminálisa felől csonkolt RANTES, mint kemokinantagonista
BR0309238A (pt) Antagonistas de proteìnas mcp
ATE231852T1 (de) Bicyclische aromatische verbindungen
MX9307983A (es) Derivados de aminoacidos de heterociclos como inhibidores de la proteina quinasa c.
RU2001132140A (ru) Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике
ATE321856T1 (de) Humane rezeptortyrosinkinase
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
FR2748938A1 (fr) Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
ATE81467T1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
BR9708297A (pt) Compostos composição farmacéutica cosmposição e uso de uma composição cosmética
ATE289611T1 (de) Peptide und pharmazeutische zusammensetzungen, die diese enthalten
Dziankowska-Bartkowiak et al. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
CA2487331A1 (en) Anti-inflammatory compositions and methods of use

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MM1K Lapsed by not paying the annual fees